| Metastatic clear cell renal cell carcinoma: A review of current therapies and novel immunotherapies JS Thomas, F Kabbinavar Critical reviews in oncology/hematology 96 (3), 527-533, 2015 | 65 | 2015 |
| Molecular profiling of melanoma brain metastases compared to primary cutaneous melanoma and to extracranial metastases GK In, K Poorman, M Saul, S O’Day, JM Farma, AJ Olszanski, MS Gordon, ... Oncotarget 11 (33), 3118, 2020 | 33 | 2020 |
| Metastasis of untreated head and neck cancer to percutaneous gastrostomy tube exit sites K Sheykholeslami, J Thomas, N Chhabra, T Trang, R Rezaee American journal of otolaryngology 33 (6), 774-778, 2012 | 21 | 2012 |
| A first-in-human study of AO-176, a highly differentiated anti-CD47 antibody, in patients with advanced solid tumors. HA Burris III, AI Spira, MH Taylor, OO Yeku, JF Liu, PN Munster, ... Journal of Clinical Oncology 39 (15_suppl), 2516-2516, 2021 | 19 | 2021 |
| A phase I study of intravenous fenretinide (4-HPR) for patients with malignant solid tumors JS Thomas, AB El-Khoueiry, BJ Maurer, S Groshen, JK Pinski, E Cobos, ... Cancer chemotherapy and pharmacology 87, 525-532, 2021 | 17 | 2021 |
| P860 Results from a combination of OX40 (PF-04518600) and 4–1BB (utomilumab) agonistic antibodies in melanoma and non-small cell lung cancer in a phase 1 dose expansion cohort A Chiappori, J Thompson, F Eskens, JP Spano, T Doi, O Hamid, A Diab, ... Journal for ImmunoTherapy of Cancer 8 (Suppl 1), 2020 | 15 | 2020 |
| A first-in-human phase I study of sEphB4-HSA in patients with advanced solid tumors with expansion at the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) A El-Khoueiry, B Gitlitz, S Cole, D Tsao-Wei, A Goldkorn, D Quinn, ... European Journal of Cancer 1 (69), S11, 2016 | 15 | 2016 |
| A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with … J Rodon, E Rodriguez, ML Maitland, FYC Tsai, MA Socinski, JD Berlin, ... ESMO open 9 (4), 102961, 2024 | 14 | 2024 |
| A phase II, open-label study of tomivosertib (eFT508) added on to continued checkpoint inhibitor therapy in patients (pts) with insufficient response to single-agent treatment. AB El-Khoueiry, N Tchekmedyian, RE Sanborn, JA Peguero, K Pulver, ... Journal of Clinical Oncology 38 (15_suppl), 3112-3112, 2020 | 12 | 2020 |
| A phase Ib study of guadecitabine and durvalumab in patients with advanced hepatocellular carcinoma, pancreatic adenocarcinoma, and biliary cancers. S Algaze, DL Hanna, NS Azad, JS Thomas, S Iqbal, D Habib, Y Ning, ... Journal of Clinical Oncology 40 (4_suppl), 574-574, 2022 | 11 | 2022 |
| Leveraging innate immunity with AFM24, a novel CD16A and epidermal growth factor receptor (EGFR) bispecific innate cell engager: Interim results for the non-small cell lung … AB El-Khoueiry, D Rivas, SH Lee, JS Thomas, YJ Kim, A Cervantes, ... J. Clin. Oncol 41 (1), 10.1200, 2023 | 8 | 2023 |
| A phase 2 open-label study of conditionally active biologic ozuriftamab vedotin (BA3021) in failed PD-1/L1 treatment of patients with recurrent or metastatic squamous cell … AL Ho, D Adkins, JH Lorch, JS Thomas, JS Grewal Journal of Clinical Oncology 41 (16_suppl), TPS6107-TPS6107, 2023 | 7 | 2023 |
| 778 Botensilimab, a novel innate/adaptive immune activator, plus or minus balstilimab (anti-PD-1) in “cold” and IO refractory metastatic solid tumors B Wilky, A El-Khoueiry, A Bullock, A Tsimberidou, D Mahadevan, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | 7 | 2022 |
| Making sense of forensic genetics. What can DNA tell you about a crime? T Brown, L Geddes, P Gill, E Jesper-Mir, M Kayser, C Phillips, ... Newcastle University, 2017 | 6 | 2017 |
| Phase 1b trial of IFx-Hu2. 0, a novel personalized cancer vaccine, in checkpoint inhibitor resistant merkel cell carcinoma and cutaneous squamous cell carcinoma. AS Brohl, J Markowitz, Z Eroglu, AW Silk, JR Hyngstrom, NI Khushalani, ... Journal of Clinical Oncology 41 (16_suppl), 9534-9534, 2023 | 5 | 2023 |
| Hepatic storage and maximal biliary transport of sulfobromophthalein in patients with portal hypertension WC Maddrey, J Thomas, AK Basu, FL Iber The Johns Hopkins medical journal 124 (3), 157-162, 1969 | 5 | 1969 |
| Preliminary results from the phase 2 study of AFM24 in combination with atezolizumab in patients with EGFR wild-type (EGFR-WT) non-small cell lung cancer (NSCLC). HR Kim, O Saavedra, A Cervantes, IA Lugowska, A Oberoi, ... Journal of Clinical Oncology 42 (16_suppl), 2522-2522, 2024 | 4 | 2024 |
| A phase 1/2a open label, multicenter study to assess the safety, tolerability, pharmacokinetics, and efficacy of AFM24 in patients with advanced solid cancers: Study design and … O Saavedra Santa Gadea, E Garralda, JS Lopez, MM Awad, JS Thomas, ... Journal of Clinical Oncology 40 (16_suppl), TPS2672-TPS2672, 2022 | 4 | 2022 |
| Effect of intratumoral INT230-6 on tumor necrosis and promotion of a systemic immune response: Results from a multicenter phase 1/2 study of solid tumors with and without … JS Thomas, AB El-Khoueiry, AJ Olszanski, NS Azad, GF Whalen, ... Journal of Clinical Oncology 40 (16_suppl), 2520-2520, 2022 | 4 | 2022 |
| Cutaneous malignancies of the head and neck GK In, JS Thomas, AW Silk Hematology/Oncology Clinics 35 (5), 991-1008, 2021 | 4 | 2021 |
